

### **Golodirsen Market**

Market Report | 2025-05-01 | 295 pages | Datastring Consulting

#### **AVAILABLE LICENSES:**

- Multi User License \$1399.00

#### Report description:

Description

The market, for Golodirsen was estimated at \$356.0 million in 2024; and it is anticipated to increase to \$980.8 million by 2030 with projections indicating a growth to around \$2.3 billion by 2035. This expansion represents a compound annual growth rate (CAGR) of 18.4% over the forecast period.

Segmentation

To see report segmentation please view the table of contents, or ask us for samples.

#### **Table of Contents:**

Chapter 1: Executive Summary - Major Markets & Their Performance - Statistical Snapshots

Chapter 2: Research Methodology

- 2.1: Axioms & Postulates
- 2.2: Market Introduction & Research Methodology Estimation & Forecast Parameters / Major Databases & Sources

Chapter 3: Market Dynamics

- 3.1: Market Overview Drivers / Restraints / Opportunities / M4 Factors
- 3.2: Market Trends
- 3.2.1: Introduction & Narratives
- 3.2.2: Market Trends Impact Analysis (Short, Medium & Long Term Impacts)
- 3.3: Supply Chain Analysis
- 3.4: Porter's Five Forces Suppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry

Chapter 4: Global Golodirsen Market Size, Opportunities & Strategic Insights, by Patient Group

- 4.1: Pediatric
- 4.2: Adolescent
- 4.3: Adult

Chapter 5: Global Golodirsen Market Size, Opportunities & Strategic Insights, by Application

Scotts International, EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

- 5.1: Therapeutic Treatment
- 5.2: Experimental Procedures
- 5.3: Medical Research
- 5.4: Others

Chapter 6: Global Golodirsen Market Size, Opportunities & Strategic Insights, by Distribution Channel

- 6.1: Hospital Pharmacies
- 6.2: Retail Pharmacies
- 6.3: Online Pharmacies

Chapter 7: Golodirsen Market, by Region

- 7.1: North America Golodirsen Market Size, Opportunities, Key Trends & Strategic Insights
- 7.1.1: U.S.
- 7.1.2: Canada
- 7.2: Europe Golodirsen Market Size, Opportunities, Key Trends & Strategic Insights
- 7.2.1: Germany
- 7.2.2: France
- 7.2.3: UK
- 7.2.4: Italy
- 7.2.5: The Netherlands
- 7.2.6: Rest of EU
- 7.3: Asia Pacific Golodirsen Market Size, Opportunities, Key Trends & Strategic Insights
- 7.3.1: China
- 7.3.2: Japan
- 7.3.3: South Korea
- 7.3.4: India
- 7.3.5: Australia
- 7.3.6: Thailand
- 7.3.7: Rest of APAC
- 7.4: Middle East & Africa Golodirsen Market Size, Opportunities, Key Trends & Strategic Insights
- 7.4.1: Saudi Arabia
- 7.4.2: United Arab Emirates
- 7.4.3: South Africa
- 7.4.4: Rest of MEA
- 7.5: Latin America Golodirsen Market Size, Opportunities, Key Trends & Strategic Insights
- 7.5.1: Brazil
- 7.5.2: Mexico
- 7.5.3: Rest of LA
- 7.6: CIS Golodirsen Market Size, Opportunities, Key Trends & Strategic Insights
- 7.6.1: Russia
- 7.6.2: Rest of CIS

Chapter 8: Competitive Landscape

- 8.1: Competitive Dashboard & Market Share Analysis
- 8.2: Company Profiles (Overview, Financials, Developments, SWOT)
- 8.2.1: Sarepta Therapeutics
- 8.2.2: Pfizer
- 8.2.3: Novartis
- 8.2.4: Sanofi
- 8.2.5: GlaxoSmithKline

## Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

8.2.6: F. Hoffmann-La Roche

8.2.7: Biogen

8.2.8: Vertex Pharmaceuticals

8.2.9: Eli Lilly and Company

8.2.10: Genzyme

8.2.11: Bristol-Myers Squibb

8.2.12: Celgene

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com



☐ - Print this form

To place an Order with Scotts International:

# **Golodirsen Market**

Market Report | 2025-05-01 | 295 pages | Datastring Consulting

<ul><li>Complete the re</li></ul>	elevant blank fields ar	nd sign			
<ul><li>Send as a scanr</li></ul>	ned email to support@	scotts-international.com			
ORDER FORM:					
Select license	License	License			
	Multi User License	Multi User License			
			VAT		
*Di			Total	4.0	
			ort@scotts-international.com or 0048 603 394 3 sed companies who are unable to provide a valio		
U VAT WIII be added a	t 25 /0 101 1 011311 based t	ompanies, individuals and Lo bas	sed companies who are unable to provide a valid	LO Vat Numbe	
Email*		Phone*			
First Name*		Last Name*			
Job title*					
Company Name*		EU Vat / Tax	EU Vat / Tax ID / NIP number*		
Address*		City*			
Zip Code*		Country*			
		Date	2025-06-07		
		Signature			